In this article, we will be looking at the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts.

On May 13, Reuters reported that Morgan Stanley increased its annual target for the benchmark S&P 500 index. The brokerage said US stocks still have room to rise higher as companies continue to deliver strong earnings results.

Morgan Stanley raised its annual target for the index from 7,800 to 8,000. The new target suggests an upside of 8% from Tuesday’s closing level of 7,400 points.

The firm set per-share earnings estimates for S&P 500 companies for 2026 at $339, which is an increase of 23% compared to the previous year. This is based on expectations of efficiency gains from wider AI adoption and better pricing power among companies.

Morgan Stanley said that its “bullish index ​view is an earnings story, not a multiple expansion one.” The brokerage added that valuations could slightly compress as hopes for near-term interest rate cuts fade.

According to LSEG data, around 83.2% of the 440 S&P 500 companies that have reported first-quarter earnings by May 8 surpassed analyst expectations.

Morgan Stanley pointed out that over ​the next 12 months, it sees “the rolling recovery continuing to progress, driven by a ​strong earnings environment as positive operating leverage persists and is further enhanced by AI adoption.”

With this background in mind, let’s take a look at the 10 best aggressive growth stocks to buy according to Wall Street analysts.

Our Methodology

To compile our list of the 10 best aggressive growth stocks to buy according to Wall Street analysts, we looked for stocks with a year-over-year revenue growth rate exceeding 35%. To ensure the reliability of our findings, we consulted Seeking Alpha to confirm the year-over-year revenue growth rate for each company. Next, we focused on the top 10 stocks that analysts believe have the most potential for growth. We ranked the 10 best aggressive growth stocks to buy based on their average price target upside potential according to analysts as of May 12, 2026. These stocks are also popular among elite hedge funds.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts

10. BeOne Medicines AG (NASDAQ:ONC)

Year-Over-Year Revenue Growth: 37.44%

Average Price Target Upside Potential According to Analysts: 32.58%

Number of Hedge Fund Holders: 27

BeOne Medicines AG (NASDAQ:ONC) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 7, Guggenheim analyst Michael Schmidt increased the firm’s price target from $410 to $420 while maintaining a Buy rating on the stock.

This update comes after the company reported a topline beat in Q1 and raised its 2026 guidance. Guggenheim updated its model following the quarterly results and called BeOne Medicines AG (NASDAQ:ONC) its top mid-cap stock pick.

The company reported total global revenue of $1.5 billion, up 35% compared to the same period last year. Foundational BRUKINSA (zanubrutinib) global revenues reached $1.1 billion, up 38% year-over-year.

Additionally, BeOne Medicines AG (NASDAQ:ONC) reported improved profitability as gross margin as a percentage of global product sales rose to 89% for the first quarter, compared to 85% in the same period last year on a GAAP basis.

The company said this improvement was mainly driven by a proportionally higher sales mix of global BRUKINSA compared to other products in its portfolio. Lower costs for both BRUKINSA and TEVIMBRA, helped by productivity improvements, also supported the increase in margins.

BeOne Medicines AG (NASDAQ:ONC) is a global oncology company focused on discovering and developing innovative treatments for cancer patients worldwide.

9. Venture Global, Inc. (NYSE:VG)

Year-Over-Year Revenue Growth: 176.93%

Average Price Target Upside Potential According to Analysts: 33.39%

Number of Hedge Fund Holders: 22

Venture Global, Inc. (NYSE:VG) is one of the best aggressive growth stocks to buy according to Wall Street analysts. On May 12, Venture Global, Inc. (NYSE:VG) reported that it has executed two binding agreements to supply additional US liquefied natural gas (LNG).

The company announced a new, binding agreement with TotalEnergies SE (NYSE:TTE), under which Venture Global, Inc. (NYSE:VG) will supply around 0.85 million tonnes per annum (MTPA) of LNG for about 5 years, starting in 2026.

Separately, the company entered into an agreement with Vitol to increase the existing five-year binding LNG deal to 1.7 MTPA, up from the previously agreed 1.5 MTPA announced in March 2026. Both of these binding agreements will be supplied from Venture Global, Inc.’s (NYSE:VG) LNG portfolio.

The company said that following these deals, its total LNG capacity sold under five-year agreements has now exceeded 3 MTPA.

Venture Global, Inc. (NYSE:VG) is an American company that produces and exports liquefied natural gas (LNG).